775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

Sands, Bruce E.; Irving, Peter M.; Hoops, Timothy; Izanec, James; Gao, Lei; Gasink, Christopher; Greenspan, Andrew; Allez, Matthieu; Danese, Silvio; Hanauer, Stephen B.; Jairath, Vipul; Kuehbacher, Tanja; Loftus, Edward V.; Mihály, Emese; Panaccione, Remo; Scherl, Ellen; Щукина, О. Б.; Sandborn, William J.

doi:10.1053/j.gastro.2021.06.040

Cited by 23 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conclusively, we found that the risk of tuberculosis appears to be low in patients with IBD who were treated with vedolizumab or ustekinumab in South Korea. Considering that vedolizumab and ustekinumab showed similar therapeutic effects compared with TNF inhibitors, 19 20 based on this study we suggest that these two novel agents could be regarded as optimal first-line choices for patients with IBD, in a country where the burden of tuberculosis is substantial, including South Korea.…”

mentioning

confidence: 71%

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

Choi

Yang

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical records of 238 patients with IBD who received vedolizumab or ustekinumab were retrospectively reviewed at a tertiary referral center in South Korea. All patients had ≥ 3 months of follow-up duration and underwent a latent tuberculosis infection screening test before initiation of the administration of these drugs. Of the 238 patients enrolled, 181 had Crohn’s disease, and 57 had ulcerative colitis. During the median 18.7 months of follow-up, active tuberculosis did not develop in any patient treated with vedolizumab or ustekinumab. Therefore, we concluded that the risk of tuberculosis appears to be low in patients with IBD treated with vedolizumab or ustekinumab in South Korea.

show abstract

mentioning

confidence: 71%

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

Choi

Yang

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…The only head-to-head randomized controlled trial of biologic therapies in CD was SEAVUE, which did not demonstrate any significant statistical differences in clinical or endoscopic remission in patients treated with ustekinumab as compared with adalimumab (9). However, it remains possible that disease distribution was different in ustekinumab-treated patients compared with adalimumab-treated patients, and breakdown of EH by segment could further inform the utility of these biologics for treating CD.…”

Section: Discussionmentioning

confidence: 98%

Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

INTRODUCTION: We compared the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohn's disease (CD). METHODS:This was a pooled analysis of patient-level data from 299 patients with CD from 4 clinical trials.Proportions of patients treated with each biologic were compared for achieving 1-year complete EH (Simple Endoscopic Score for CD [SES-CD] <3) and ileal and colonic EH separately (SES-CD 5 0). Multivariate logistic regression was used to model the relationship between biologics and 1-year outcomes and adjusted for disease duration, concomitant corticosteroid use, and prior antitumor necrosis factor failure.

show abstract

“…The first head to head in Crohn's disease was recently presented at Digestive Disease Week (DDW) 2021( Sands et al., 2021 ) and European Crohn's and Colitis Organization (ECCO) congress 2021( Irving et al., 2021 ). The SEAVUE study compared ustekinumab with adalimumab in 386 bio-naïve patients with moderate to severe CD over 52 weeks.…”

Section: Comparative Efficacy Of Available Biological Agentsmentioning

confidence: 99%

“…The second is ustekinumab, a humanized monoclonal antibody to the interleukin (IL) p40 subunit common to IL12/23. These new agents have now proved their efficacy not only against placebo but also in head-to-head trials against anti-TNF agents in specific indications ( Sands et al., 2019 , 2021 ; Irving et al., 2021 ). Consequently, they possess a comfortable market position compared to the historical anti-TNF agents, when not surpassing them for certain targeted groups of patients.…”

Section: Introductionmentioning

confidence: 99%

Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?

Juillerat

Grueber

Ruetsch

et al. 2022

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

Cited by 23 publications

References 0 publications

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea

Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease

Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?

Contact Info

Product

Resources

About